From the Journals

The Genetic Switch in Pancreatic Cancer 

New research explains how a common cancer gene alters tumor type and may influence treatment response

  • March 13, 2026

  • 3 min

Share

Research published in the Journal of Clinical Investigation reveals how the KRAS signaling pathway influences the aggressiveness of pancreatic cancer by suppressing the GATA6 gene. GATA6 is crucial for tumor cell differentiation; high levels indicate a less aggressive cancer subtype with better treatment responses. When KRAS is active, it stabilizes JUNB, decreasing GATA6 activity and leading to a more aggressive tumor profile. Blocking the KRAS pathway can restore GATA6 activity, enhancing chemotherapy effectiveness, particularly with oxaliplatin, suggesting new therapeutic strategies.

Original Source(s)

The Genetic Switch in Pancreatic Cancer 

  • March 13, 2026

Related Content

Building Quality into Advanced Therapies from Day One

Why early, risk-based thinking is critical in cell and gene therapy development

  • March 13, 2026

  • 7 min
Engineering Safer Editors for Cystic Fibrosis Mutations 

Modified APOBEC3G editors improve CRISPR base-editing specificity and reduce bystander mutations in human cells

  • March 13, 2026

  • 2 min
Deep-UV Raman Reveals mRNA Encapsulation in Lipid Nanoparticles 

Spectroscopic analysis reveals lipid–RNA interactions governing nanoparticle formulation efficiency 

  • March 13, 2026

  • 2 min